---
title: "BBOT.US (BBOT.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/BBOT.US/news.md"
symbol: "BBOT.US"
name: "BBOT.US"
parent: "https://longbridge.com/zh-HK/quote/BBOT.US.md"
datetime: "2026-03-14T21:17:12.114Z"
locales:
  - [en](https://longbridge.com/en/quote/BBOT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BBOT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BBOT.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/BBOT.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/BBOT.US/news.md)


# BBOT.US (BBOT.US) — 相關新聞

### [BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028](https://longbridge.com/zh-HK/news/278977292.md)
*2026-03-13T03:18:32.000Z*
> BridgeBio Oncology (NASDAQ: BBOT) presented its next-generation RAS therapeutics strategy at the Leerink Partners’ Globa

### [BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility](https://longbridge.com/zh-HK/news/278209924.md)
*2026-03-07T06:00:10.000Z*
> BridgeBio Oncology Therapeutics, Inc. (BBOT) has raised concerns regarding its concentration risk by focusing heavily on

### [BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor | BBOT Stock News](https://longbridge.com/zh-HK/news/278127661.md)
*2026-03-06T07:07:00.000Z*
> BBOT has announced the publication of preclinical data on BBO-11818, a potent panKRAS inhibitor, in the journal Cancer D

### [BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo Tolerability](https://longbridge.com/zh-HK/news/276975538.md)
*2026-02-26T03:10:32.000Z*
> BridgeBio Oncology Therapeutics (NASDAQ: BBOT) executives presented their strategy for a "Best in RAS" pipeline during a

### [BridgeBio Oncology Therapeutics awarded inducement grants on Feb 10, 2026, to two individuals hired in Jan 2026.](https://longbridge.com/zh-HK/news/276026157.md)
*2026-02-16T02:29:52.000Z*
> On February 10, 2026, BridgeBio Oncology Therapeutics, Inc. (BBOT) based in South San Francisco made public the awarding

### [BridgeBio Oncology Therapeutics awards inducement grants to two new employees as part of 2025 Inducement Plan.](https://longbridge.com/zh-HK/news/275958172.md)
*2026-02-14T00:57:02.000Z*
> On February 11, 2026, BridgeBio Oncology Therapeutics, Inc. (BBOT), a company specializing in RAS-pathway malignancies, 

### [BridgeBio Oncology Therapeutics Grants Stock Options Under 2025 Inducement Plan](https://longbridge.com/zh-HK/news/275656495.md)
*2026-02-11T21:05:10.000Z*
### [](https://longbridge.com/zh-HK/news/275653973.md)
*2026-02-11T19:47:07.000Z*
> BridgeBio Oncology shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announce